Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Net Cash Flow came in at -$5.3 million in Q4 2025, down 23043.98% on a YoY basis from N/an in Q4 2024, and down 205.94% quarter-over-quarter from -$1.7 million in Q3 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Net Cash Flow for 2 consecutive years, with -$5.3 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow fell 23043.98% year-over-year to -$5.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (up 424.75% YoY), and the FY2025 full-year result was $1.6 million, up 501.25% from the prior year.
- Net Cash Flow eased to -$5.3 million in Q4 2025 per APUS's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $8.5 million in Q2 2025 and bottomed at -$5.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | 246,887.00 |
| Dec 31, 2024 | -23,116.00 |
| Sep 30, 2024 | -36,755.00 |
| Jun 30, 2024 | -184,055.00 |
| Mar 31, 2024 | -263,100.00 |